190 related articles for article (PubMed ID: 37958700)
21. Current and emerging biomarkers in ovarian cancer diagnosis; CA125 and beyond.
Sharma T; Nisar S; Masoodi T; Macha MA; Uddin S; Akil AA; Pandita TK; Singh M; Bhat AA
Adv Protein Chem Struct Biol; 2023; 133():85-114. PubMed ID: 36707207
[TBL] [Abstract][Full Text] [Related]
22. A machine learning approach applied to gynecological ultrasound to predict progression-free survival in ovarian cancer patients.
Arezzo F; Cormio G; La Forgia D; Santarsiero CM; Mongelli M; Lombardi C; Cazzato G; Cicinelli E; Loizzi V
Arch Gynecol Obstet; 2022 Dec; 306(6):2143-2154. PubMed ID: 35532797
[TBL] [Abstract][Full Text] [Related]
23. High-throughput proteomics of breast cancer subtypes: Biological characterization and multiple candidate biomarker panels to patients' stratification.
Azevedo ALK; Gomig THB; Batista M; Marchini FK; Spautz CC; Rabinovich I; Sebastião APM; Oliveira JC; Gradia DF; Cavalli IJ; Ribeiro EMSF
J Proteomics; 2023 Aug; 285():104955. PubMed ID: 37390896
[TBL] [Abstract][Full Text] [Related]
24. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of combining salivary mRNAs and carcinoembryonic antigen for ovarian cancer detection.
Yang J; Xiang C; Liu J
Scand J Clin Lab Invest; 2021 Feb; 81(1):39-45. PubMed ID: 33300816
[TBL] [Abstract][Full Text] [Related]
26. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
El Bairi K; Kandhro AH; Gouri A; Mahfoud W; Louanjli N; Saadani B; Afqir S; Amrani M
Cell Oncol (Dordr); 2017 Apr; 40(2):105-118. PubMed ID: 27981507
[TBL] [Abstract][Full Text] [Related]
27. Identification of potential saliva and tear biomarkers in primary Sjögren's syndrome, utilising the extraction of extracellular vesicles and proteomics analysis.
Aqrawi LA; Galtung HK; Vestad B; Øvstebø R; Thiede B; Rusthen S; Young A; Guerreiro EM; Utheim TP; Chen X; Utheim ØA; Palm Ø; Jensen JL
Arthritis Res Ther; 2017 Jan; 19(1):14. PubMed ID: 28122643
[TBL] [Abstract][Full Text] [Related]
28. High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer.
Enroth S; Berggrund M; Lycke M; Broberg J; Lundberg M; Assarsson E; Olovsson M; Stålberg K; Sundfeldt K; Gyllensten U
Commun Biol; 2019; 2():221. PubMed ID: 31240259
[TBL] [Abstract][Full Text] [Related]
29. Potential Significance of Peptidome in Human Ovarian Cancer for Patients With Ascites.
Huang X; Zhou J; Tang R; Han S; Zhou X
Int J Gynecol Cancer; 2018 Feb; 28(2):355-362. PubMed ID: 29240604
[TBL] [Abstract][Full Text] [Related]
30. Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.
Kim MK; Caplen N; Chakka S; Hernandez L; House C; Pongas G; Jordan E; Annunziata CM
BMC Cancer; 2016 Aug; 16(1):678. PubMed ID: 27558154
[TBL] [Abstract][Full Text] [Related]
31. Ovarian cancer classification based on dimensionality reduction for SELDI-TOF data.
Tang KL; Li TH; Xiong WW; Chen K
BMC Bioinformatics; 2010 Feb; 11():109. PubMed ID: 20187963
[TBL] [Abstract][Full Text] [Related]
32. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry.
Xiao H; Zhang L; Zhou H; Lee JM; Garon EB; Wong DT
Mol Cell Proteomics; 2012 Feb; 11(2):M111.012112. PubMed ID: 22096114
[TBL] [Abstract][Full Text] [Related]
33. Machine learning analysis of proteomics data for early diagnosis.
Devetyarov D
Stud Health Technol Inform; 2009; 150():772. PubMed ID: 19745415
[TBL] [Abstract][Full Text] [Related]
34. Targeted Proteomics Guided by Label-free Quantitative Proteome Analysis in Saliva Reveal Transition Signatures from Health to Periodontal Disease.
Bostanci N; Selevsek N; Wolski W; Grossmann J; Bao K; Wahlander A; Trachsel C; Schlapbach R; Öztürk VÖ; Afacan B; Emingil G; Belibasakis GN
Mol Cell Proteomics; 2018 Jul; 17(7):1392-1409. PubMed ID: 29610270
[TBL] [Abstract][Full Text] [Related]
35. Ovarian cancer subtypes and survival in relation to three comprehensive imaging parameters.
Sartor H; Bjurberg M; Asp M; Kahn A; Brändstedt J; Kannisto P; Jirström K
J Ovarian Res; 2020 Mar; 13(1):26. PubMed ID: 32145749
[TBL] [Abstract][Full Text] [Related]
36. Review Insights on Salivary Proteomics Biomarkers in Oral Cancer Detection and Diagnosis.
Umapathy VR; Natarajan PM; Swamikannu B
Molecules; 2023 Jul; 28(13):. PubMed ID: 37446943
[TBL] [Abstract][Full Text] [Related]
37. Validation of candidate serum ovarian cancer biomarkers for early detection.
Su F; Lang J; Kumar A; Ng C; Hsieh B; Suchard MA; Reddy ST; Farias-Eisner R
Biomark Insights; 2007 Oct; 2():369-75. PubMed ID: 19662218
[TBL] [Abstract][Full Text] [Related]
38. Clinical potential of proteomics in the diagnosis of ovarian cancer.
Ardekani AM; Liotta LA; Petricoin EF
Expert Rev Mol Diagn; 2002 Jul; 2(4):312-20. PubMed ID: 12138495
[TBL] [Abstract][Full Text] [Related]
39. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
Boyce EA; Kohn EC
Int J Gynecol Cancer; 2005; 15 Suppl 3():266-73. PubMed ID: 16343243
[TBL] [Abstract][Full Text] [Related]
40. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
